ImmunOs Therapeutics
PrivateLast Round
Series C
Sep 17, 2024
Total Funding Raised
$100.2M
Momentum Score
50 /100
Company Overview
ImmunOs Therapeutics is a biotechnology company specializing in the development of innovative human immunomodulatory proteins and drugs aimed at treating cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunOs Therapeutics Comps
Public and private peers based on sector, stage, and business model.
ImmunOs Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 17, 2024 | ||||
| Series B | Jun 7, 2022 | ||||
| Series A | Dec 10, 2019 | ||||
| Series A | Sep 18, 2018 |
ImmunOs Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMedPartners | Series A, Series B, Series C |
| GL Capital Group | Series B |
| Gimv | Series B, Series C |
| Fiscus DAO | Series B |
| PEAK6 Investments | Series B |
| BioInnovation Capital | Series B, Series C |
| UZH Life Sciences Fund | Series A |
ImmunOs Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ImmunOs Therapeutics's valuation, stock price, and market status.
